Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vopikitug (RO7296682) in Advanced Solid Tumors
NCT04158583Phase 1Terminated
- Sponsor
- Roche
- Start
- Dec 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of vopikitug in solid tumor (10 cohorts), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Dose Limiting Toxicities up to 28 days. Started Dec 2019; status: terminated.
02
Drugs
vopikitug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04158583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158583.